Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

Jennifer Obasi; Komal Sharma; Navonil De Sarkar; Emmanuel S. Antonarakis; Deepak Kilari

doi:10.1016/j.clgc.2024.102187

Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

Jennifer Obasi
, Komal Sharma
, Navonil De Sarkar
, Emmanuel S. Antonarakis
, Deepak Kilari

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

Abstract

• PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD. • A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell. • In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.

Original language	English (US)
Article number	102187
Journal	Clinical Genitourinary Cancer
Volume	22
Issue number	6
DOIs	https://doi.org/10.1016/j.clgc.2024.102187
State	Published - Dec 2024

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Inc.

Keywords

Carboplatin
Homologous recombination repair
Homologous recombination repair deficiency
Olaparib
PARP inhibitor
PARP inhibitor resistance
Talazoparib

PubMed: MeSH publication types

Case Reports
Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.clgc.2024.102187

Find It

Find It at U of M Libraries

Cite this

@article{09dffce7880b4414ae20099e682aabe5,

title = "Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer",

abstract = " • PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD. • A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell. • In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.",

keywords = "Carboplatin, Homologous recombination repair, Homologous recombination repair deficiency, Olaparib, PARP inhibitor, PARP inhibitor resistance, Talazoparib",

author = "Jennifer Obasi and Komal Sharma and \{De Sarkar\}, Navonil and Antonarakis, \{Emmanuel S.\} and Deepak Kilari",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = dec,

doi = "10.1016/j.clgc.2024.102187",

language = "English (US)",

volume = "22",

journal = "Clinical Genitourinary Cancer",

issn = "1558-7673",

publisher = "Elsevier Inc.",

number = "6",

}

TY - JOUR

T1 - Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

AU - Obasi, Jennifer

AU - Sharma, Komal

AU - De Sarkar, Navonil

AU - Antonarakis, Emmanuel S.

AU - Kilari, Deepak

PY - 2024/12

Y1 - 2024/12

N2 - • PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD. • A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell. • In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.

AB - • PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD. • A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell. • In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.

KW - Carboplatin

KW - Homologous recombination repair

KW - Homologous recombination repair deficiency

KW - Olaparib

KW - PARP inhibitor

KW - PARP inhibitor resistance

KW - Talazoparib

UR - https://www.scopus.com/pages/publications/85203009546

UR - https://www.scopus.com/pages/publications/85203009546#tab=citedBy

U2 - 10.1016/j.clgc.2024.102187

DO - 10.1016/j.clgc.2024.102187

M3 - Article

C2 - 39241311

AN - SCOPUS:85203009546

SN - 1558-7673

VL - 22

JO - Clinical Genitourinary Cancer

JF - Clinical Genitourinary Cancer

IS - 6

M1 - 102187

ER -

Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this